Paper36765741
Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research.
Thibault B and 2 others. Cancers (Basel), 2023. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. Papers, record 36765741. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765741
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Toucan, Projet-ANR-18-CE14-0013 | Agence Nationale de la Recherche | PubMed | ||
| Project ID: 675392 | MSCA-ITN/ETN PhD-PI3K | PubMed |
Source PubMed
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28390196 | PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. | Oncotarget | 2017 | https://conductscience.org/library/papers/28390196 | PubMed |
| 2 | 17644513 | The role of phosphoinositide 3-kinase C2alpha in insulin signaling. | J Biol Chem | 2007 | https://conductscience.org/library/papers/17644513 | PubMed |
| 3 | 33740047 | Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent. | Biochem J | 2021 | https://conductscience.org/library/papers/33740047 | PubMed |
| 4 | 26132308 | Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells. | PLoS Genet | 2015 | https://conductscience.org/library/papers/26132308 | PubMed |
| 5 | 27270320 | PIK3C2A mRNA functions as a miR-124 sponge to facilitate CD151 expression and enhance malignancy of hepatocellular carcinoma cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27270320 | PubMed |
| 6 | 20876794 | Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20876794 | PubMed |
| 7 | 30055290 | Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. | Cancer Lett | 2018 | https://conductscience.org/library/papers/30055290 | PubMed |
| 8 | 28800863 | Targeting PI3K/AKT pathway in triple-negative breast cancer. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28800863 | PubMed |
| 9 | 27697050 | Hybrid Compounds as Multitarget Directed Anticancer Agents. | Curr Top Med Chem | 2017 | https://conductscience.org/library/papers/27697050 | PubMed |
| 10 | 33880878 | PI3KC2β inactivation stabilizes VE-cadherin junctions and preserves vascular integrity. | EMBO Rep | 2021 | https://conductscience.org/library/papers/33880878 | PubMed |
| 11 | 26934321 | Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. | Oncotarget | 2016 | https://conductscience.org/library/papers/26934321 | PubMed |
| 12 | 34544753 | RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34544753 | PubMed |
| 13 | 18544649 | The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18544649 | PubMed |
| 14 | 29233821 | Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. | Blood | 2018 | https://conductscience.org/library/papers/29233821 | PubMed |
| 15 | 22983395 | Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. | Nat Med | 2012 | https://conductscience.org/library/papers/22983395 | PubMed |
| 16 | 26073258 | miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β. | FEBS Lett | 2015 | https://conductscience.org/library/papers/26073258 | PubMed |
| 17 | 26342236 | Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26342236 | PubMed |
| 18 | 31911549 | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. | Cancer Res | 2020 | https://conductscience.org/library/papers/31911549 | PubMed |
| 19 | 26983806 | Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. | Sci Rep | 2016 | https://conductscience.org/library/papers/26983806 | PubMed |
| 20 | 22696681 | Phosphatidylinositol 3,5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of rapamycin 1. | Mol Biol Cell | 2012 | https://conductscience.org/library/papers/22696681 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42515723 | Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515723 | PubMed |
| 42446738 | PIK3CA mutations and PI3K isoform expression define prognostic signatures in ovarian clear cell carcinoma. | Arch Gynecol Obstet | 2026 | https://conductscience.org/library/papers/42446738 | PubMed |
| 41972724 | VPS34 in Autophagy, Cancer, and Cancer Therapy. | Cells | 2026 | https://conductscience.org/library/papers/41972724 | PubMed |
| 41754938 | Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754938 | PubMed |
| 41686813 | PIKI-1, a class II PI 3-kinase, functions in endocytic trafficking. | PLoS Genet | 2026 | https://conductscience.org/library/papers/41686813 | PubMed |
| 41422162 | Integrative analysis of scRNA-seq and RNA-seq to investigate the prognostic value of lactylation and fibroblast-related genes in intrahepatic cholangiocarcinoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/41422162 | PubMed |
| 41049266 | Breast Cancer: Molecular Pathogenesis and Targeted Therapy. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41049266 | PubMed |
| 40830981 | The role of the striatin family proteins in hippo signaling and cellular regulation. | Cell Biosci | 2025 | https://conductscience.org/library/papers/40830981 | PubMed |
| 40475523 | PIKI-1, a class II phosphatidylinositol 3-kinase, functions in endocytic trafficking. | bioRxiv | 2025 | https://conductscience.org/library/papers/40475523 | PubMed |
| 40427108 | PI3Kδ as a Novel Therapeutic Target for Aggressive Prostate Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40427108 | PubMed |
| 40027467 | A narrative review of autophagy in migraine. | Front Neurosci | 2025 | https://conductscience.org/library/papers/40027467 | PubMed |
| 39944823 | The role of ubiquitination and deubiquitination in cancer lipid metabolism. | Front Oncol | 2025 | https://conductscience.org/library/papers/39944823 | PubMed |
| 39821606 | Class III Phosphatidylinositol-3 Kinase/Vacuolar Protein Sorting 34 in Cardiovascular Health and Disease. | J Cardiovasc Transl Res | 2025 | https://conductscience.org/library/papers/39821606 | PubMed |
| 39534586 | Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy. | Transl Breast Cancer Res | 2024 | https://conductscience.org/library/papers/39534586 | PubMed |
| 39457034 | In Silico Discovery of a Novel PI3Kδ Inhibitor Incorporating 3,5,7-Trihydroxychroman-4-one Targeting Diffuse Large B-Cell Lymphoma. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39457034 | PubMed |
| 39337387 | O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337387 | PubMed |
| 39161590 | The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39161590 | PubMed |
| 39127670 | Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39127670 | PubMed |
| 38396649 | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38396649 | PubMed |
| 38332727 | Discoidin domain receptor 2 signaling through PIK3C2α in fibroblasts promotes lung fibrosis. | J Pathol | 2024 | https://conductscience.org/library/papers/38332727 | PubMed |
Genes34
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36765741
GET https://conductscience.org/api/papers/v1/36765741/references?page=2